Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference Oct 13, 2022
Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022 Oct 12, 2022
Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Oct 3, 2022
Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone Sep 21, 2022
Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone Aug 30, 2022
Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility Aug 8, 2022
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022 Aug 8, 2022